Clinical Advances and Emerging Trends in Melanoma: A Symposium at the Society for Melanoma Research 2019 Congress

0.75 CME
$0 FEE
Clinical Advances and Emerging Trends in Melanoma: A Symposium at the Society for Melanoma Research 2019 Congress


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by educational grants from Bristol-Myers Squibb; Iovance Biotherapeutics; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation.

Activity Description

Treatment for patients with advanced melanoma has been revolutionized through the integration of checkpoint inhibitors, intralesional therapies, and targeted therapies into management algorithms. With these advances, new challenges have emerged, including identifying appropriate individualized therapy regimens, selecting adjuvant therapy, sequencing of agents, and managing treatment-related adverse events. In this educational activity, experts in the field assess clinical advances pertaining to adjuvant therapies; evaluate the latest data for sequencing of therapies for patients with advanced melanoma; and discuss the patient, tumor, and/or treatment characteristics that may help guide clinical decision-making for patients with recurrent melanoma.

Target Audience

The intended audience for this activity is oncologists and other professionals interested in the latest clinical advances regarding the management of patients with melanoma.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the clinical advances regarding the adjuvant treatment of patients with melanoma and how to apply this to optimize patient outcomes.
  • Evaluate the latest clinical evidence regarding sequencing of targeted agents, checkpoint inhibitors, and other emerging options for patients with advanced melanoma, both with and without BRAF mutation.
  • Examine the patient, tumor, and/or treatment characteristics that may help guide clinical decision-making for patients with recurrent melanoma.

Activity Chair

Georgina V. Long, BSc, PhD, MBBS, FRACP
Professor of Melanoma Medical Oncology and Translational Research
Co-Medical Director Melanoma Institute Australia
The University of Sydney
North Sydney, NSW, Australia


Michael A. Davies, MD, PhD
Professor and Chair, Department of Melanoma Medical Oncology
MD Anderson Cancer Center
Houston, TX


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, March 19, 2020, through March 18, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationship(s)

Michael A. Davies, MD, PhD
Consulting Fee: Array, Bristol-Myers Squibb, Novartis
Contracted Research: Roche/Genentech, Sanofi-Aventis

Georgina V. Long, BSc, PhD, MBBS, FRACP
Consulting Fee: Amgen, Bristol-Myers Squibb, MSD/Merck, Novartis, Pierre Fabre
Contracted Research: Amgen, Bristol-Myers Squibb, MassARRAY, MSD/Merck, Novartis, Pierre Fabre, Roche
Honoraria: Bristol-Myers Squibb, MSD/Merck, Novartis, Pierre Fabre

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at